Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.
Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.